Loading...

Mesco Pharmaceuticals

BSE:500274
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
500274
BSE
₹239M
Market Cap
  1. Home
  2. IN
  3. Diversified Financials
Company description

Mesco Pharmaceuticals Limited does not have significant operations. The last earnings update was 66 days ago. More info.


Add to Portfolio Compare Print
500274 Share Price and Events
7 Day Returns
0%
BSE:500274
-0.6%
IN Capital Markets
0.8%
IN Market
1 Year Returns
-
BSE:500274
-28.4%
IN Capital Markets
-0.7%
IN Market
500274 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mesco Pharmaceuticals (500274) 0% 0% -5% - - -
IN Capital Markets -0.6% 0.7% -1.8% -28.4% 57.3% 133.1%
IN Market 0.8% 2.1% 5.8% -0.7% 41.2% 72.5%
1 Year Return vs Industry and Market
  • No trading data on 500274.
  • No trading data on 500274.
Price Volatility
Industry
5yr Volatility vs Market

500274 Value

 Is Mesco Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mesco Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mesco Pharmaceuticals.

BSE:500274 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Excess Returns Model
Stable EPS Last reported Return on Equity.
= Stable Book Value * Return on Equity
= ₹-5.24 * 3.8%
₹-0.20
Book Value of Equity per Share Median Book Value from the past 5 years. ₹-5.24
Discount Rate (Cost of Equity) See below 17%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BSE:500274
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Capital Markets Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 35%) (45.03%))
1.097
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (1.097 * 8.6%)
16.98%

Discounted Cash Flow Calculation for BSE:500274 using Excess Returns Model Model

The calculations below outline how an intrinsic value for Mesco Pharmaceuticals is arrived at using the Excess Return Model. This approach is used for finance firms where free cash flow is difficult to estimate.

In the Excess Return Model the value of a firm can be written as the sum of capital invested currently in the firm and the present value of excess returns that the firm expects to make in the future.

The model is sensitive to the Return on Equity of the company versus the Cost of Equity, how these are calculated is detailed below the main calculation.

Note the calculations below are per share.

See our documentation to learn about this calculation.

BSE:500274 Value of Excess Returns
Calculation Result
Excess Returns = (Stable Return on equity – Cost of equity) (Book Value of Equity per share)
= (3.8% – 16.98%) * ₹-5.24)
₹0.69
Terminal Value of Excess Returns = Excess Returns / (Cost of Equity - Expected Growth Rate)
= ₹0.69 / (16.98% - 7.55%)
₹7.30
Value of Equity = Book Value per share + Terminal Value of Excess Returns
= ₹-5.24 + ₹7.30
₹2.06
BSE:500274 Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹2.06
Current discount Discount to share price of ₹11.78
= -1 x (₹11.78 - ₹2.06) / ₹2.06
-471.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Mesco Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mesco Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mesco Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:500274 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹-0.19
BSE:500274 Share Price ** BSE (2019-01-21) in INR ₹11.78
India Capital Markets Industry PE Ratio Median Figure of 171 Publicly-Listed Capital Markets Companies 14.57x
India Market PE Ratio Median Figure of 2,738 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mesco Pharmaceuticals.

BSE:500274 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:500274 Share Price ÷ EPS (both in INR)

= 11.78 ÷ -0.19

-63.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mesco Pharmaceuticals is loss making, we can't compare its value to the IN Capital Markets industry average.
  • Mesco Pharmaceuticals is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Mesco Pharmaceuticals's expected growth come at a high price?
Raw Data
BSE:500274 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -63.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Capital Markets Industry PEG Ratio Median Figure of 12 Publicly-Listed Capital Markets Companies 1.57x
India Market PEG Ratio Median Figure of 584 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mesco Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mesco Pharmaceuticals's assets?
Raw Data
BSE:500274 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹-5.49
BSE:500274 Share Price * BSE (2019-01-21) in INR ₹11.78
India Capital Markets Industry PB Ratio Median Figure of 267 Publicly-Listed Capital Markets Companies 0.69x
India Market PB Ratio Median Figure of 3,628 Publicly-Listed Companies 1.11x
BSE:500274 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:500274 Share Price ÷ Book Value per Share (both in INR)

= 11.78 ÷ -5.49

-2.15x

* Primary Listing of Mesco Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mesco Pharmaceuticals has negative assets, we can't compare the value of its assets to the IN Capital Markets industry average.
X
Value checks
We assess Mesco Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. Mesco Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

500274 Future Performance

 How is Mesco Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mesco Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.3%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mesco Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Mesco Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Mesco Pharmaceuticals's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Mesco Pharmaceuticals's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BSE:500274 Future Growth Rates Data Sources
Data Point Source Value (per year)
India Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 15.3%
India Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 14.9%
India Market Earnings Growth Rate Market Cap Weighted Average 18.5%
India Market Revenue Growth Rate Market Cap Weighted Average 11.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:500274 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:500274 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 -4
2018-09-30 -4
2018-06-30 -1
2018-03-31 -1 -1
2017-12-31 -3
2017-09-30 -3
2017-06-30 -3
2017-03-31 -3 -3
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Mesco Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Mesco Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:500274 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Mesco Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500274 Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 -0.19
2018-09-30 -0.21
2018-06-30 -0.03
2018-03-31 -0.04
2017-12-31 -0.19
2017-09-30 -0.13
2017-06-30 -0.18
2017-03-31 -0.13
2016-12-31 0.00
2016-09-30 0.00
2016-06-30
2016-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mesco Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Mesco Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  2. Mesco Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Mesco Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mesco Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

500274 Past Performance

  How has Mesco Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mesco Pharmaceuticals's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mesco Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Mesco Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mesco Pharmaceuticals's 1-year growth to the IN Capital Markets industry average as it is not currently profitable.
Earnings and Revenue History
Mesco Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mesco Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:500274 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -4.05 0.17
2018-09-30 -4.11 0.24
2018-06-30 -0.66 0.22
2018-03-31 -0.87 0.40
2017-12-31 -3.10 0.44
2017-09-30 -3.07 0.42
2017-06-30 -3.03 0.39
2017-03-31 -2.59 0.40
2016-12-31 0.00 0.20
2016-09-30 0.07 0.16
2016-06-30 0.14 0.09
2016-03-31 0.21 0.02
2015-12-31 -106.13 0.02
2015-09-30 -223.85
2015-06-30 -341.59
2015-03-31 -461.37 0.00
2014-03-31 -0.02 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mesco Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Mesco Pharmaceuticals has efficiently used its assets last year compared to the IN Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mesco Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Mesco Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mesco Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

500274 Health

 How is Mesco Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mesco Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mesco Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Mesco Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mesco Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Mesco Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mesco Pharmaceuticals Company Filings, last reported 3 months ago.

BSE:500274 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -108.92 107.79 0.40
2018-09-30 -108.92 107.79 0.40
2018-06-30 -105.05 107.46 0.40
2018-03-31 -105.05 107.46 0.40
2017-12-31 -104.81 107.23 0.40
2017-09-30 -104.81 107.23 0.40
2017-06-30 -104.18 106.58 0.39
2017-03-31 -104.18 106.58 0.39
2016-12-31 -101.74 104.08 0.39
2016-09-30 -101.74 104.08 0.39
2016-06-30 -101.59 103.94 0.39
2016-03-31 -101.59 103.94 0.39
2015-12-31 -101.81 112.03 0.40
2015-09-30 -101.81 112.03 0.40
2015-06-30 -101.80 111.82 0.02
2015-03-31 -101.80 111.82 0.02
2014-03-31 359.57 109.76 0.83
  • Mesco Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Mesco Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mesco Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Mesco Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 43.5% each year.
X
Financial health checks
We assess Mesco Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mesco Pharmaceuticals has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

500274 Dividends

 What is Mesco Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mesco Pharmaceuticals dividends.
If you bought ₹2,000 of Mesco Pharmaceuticals shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mesco Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mesco Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:500274 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 61 Stocks 1.5%
India Market Average Dividend Yield Market Cap Weighted Average of 1400 Stocks 1.3%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 1.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mesco Pharmaceuticals has not reported any payouts.
  • Unable to verify if Mesco Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mesco Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mesco Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mesco Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mesco Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mesco Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

500274 Management

 What is the CEO of Mesco Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Mesco Pharmaceuticals has no CEO, or we have no data on them.
Management Team

Santosh Jha

TITLE
Chief Financial Officer

Nurani Parameswaran

TITLE
Company Secretary & Compliance Officer
AGE
82
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Mesco Pharmaceuticals board of directors in years:

3
Average Tenure
60.5
Average Age
  • The tenure for the Mesco Pharmaceuticals board of directors is about average.
Board of Directors

Rajeev Moudgil

TITLE
Independent Director
AGE
54
TENURE
3 yrs

Savita Sethi

TITLE
Independent Director
AGE
45
TENURE
2.8 yrs

Jitendra Singh

TITLE
Non-Executive Director
AGE
73

Dushyant Singh

TITLE
Non-Executive Director
AGE
67
TENURE
32.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Mesco Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mesco Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

500274 News

Simply Wall St News

500274 Company Info

Description

Mesco Pharmaceuticals Limited does not have significant operations. The company was founded in 1986 and is based in New Delhi, India.

Details
Name: Mesco Pharmaceuticals Limited
500274
Exchange: BSE
Founded: 1986
₹239,369,600
20,320,000
Website: http://www.mescopharma.com
Address: Mesco Pharmaceuticals Limited
H-1, Zamrudpur Community Centre,
Kailash Colony,
New Delhi,
Delhi, 110 048,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 500274 Equity Shares Mumbai Stock Exchange IN INR 04. Dec 2018
Number of employees
Current staff
Staff numbers
5
Mesco Pharmaceuticals employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 12:33
End of day share price update: 2019/01/21 00:00
Last earnings filing: 2019/02/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.